Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M197,562Revenue (TTM) $M49,778Net Margin (%)13.6Altman Z-Score2.5
Enterprise Value $M214,072EPS (TTM) $2.8Operating Margin %17.0Piotroski F-Score5
P/E(ttm)28.2Beneish M-Score-2.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book2.710-y EBITDA Growth Rate %-0.7Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-3.8Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow21.6y-y EBITDA Growth Rate %-16.8ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.4PEG--ROE % (ttm)9.0Less Shares Outstanding y-yY
Payout Ratio %98.0Shares Outstanding M2,381ROIC % (ttm)7.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2016-06-30 Reduce-0.05%$71.4 - $82.51
($77.03)
$ 79.643%Reduce -1.53%44,366,511
NVSTweedy Browne 2016-06-30 Reduce-0.01%$71.4 - $82.51
($77.03)
$ 79.643%Reduce -1.63%233,783
NVSKen Fisher 2016-06-30 Add0.01%$71.4 - $82.51
($77.03)
$ 79.643%Add 1.22%6,363,641
NVSMario Gabelli 2016-06-30 Reduce$71.4 - $82.51
($77.03)
$ 79.643%Reduce -12.38%6,015
NVSJohn Rogers 2016-06-30 Add$71.4 - $82.51
($77.03)
$ 79.643%Add 11.45%14,818
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 79.645%Add 1.59%6,287,099
NVSTom Gayner 2016-03-31 Buy 0.01%$71.11 - $86.21
($76.1)
$ 79.645%New holding3,700
NVSTweedy Browne 2016-03-31 Reduce-0.01%$71.11 - $86.21
($76.1)
$ 79.645%Reduce -1.87%237,664
NVSJohn Rogers 2016-03-31 Add$71.11 - $86.21
($76.1)
$ 79.645%Add 18.01%13,296
NVSMario Gabelli 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 79.645%Reduce -7.10%6,865
NVSDodge & Cox 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 79.645%Reduce -0.12%45,054,916
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 79.64-10%Reduce -1.35%45,107,085
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 79.64-10%Reduce -3.15%27,643
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 79.64-10%Reduce -2.74%242,201
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 79.64-10%Add 0.92%6,188,893
NVSJohn Rogers 2015-12-31 Buy 0.01%$83.96 - $95.03
($88.53)
$ 79.64-10%New holding11,267
NVSMario Gabelli 2015-12-31 Reduce$83.96 - $95.03
($88.53)
$ 79.64-10%Reduce -1.99%7,390
NVSDodge & Cox 2015-09-30 Reduce-0.2%$89.52 - $106.12
($99.32)
$ 79.64-20%Reduce -4.68%45,723,035
NVSKen Fisher 2015-09-30 Add0.02%$89.52 - $106.12
($99.32)
$ 79.64-20%Add 1.28%6,132,211
NVSTweedy Browne 2015-09-30 Reduce-0.01%$89.52 - $106.12
($99.32)
$ 79.64-20%Reduce -2.04%249,022
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15428.8view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    Pharmaceuticals are the New Bonds Aug 30 2016 
    Merck Offers Value and Steady Dividend Growth Aug 24 2016 
    Novartis: First-Class Pharmaceuticals Aug 19 2016 
    Novartis Needs to Stem the Bleeding From Gleevec Decline Aug 16 2016 
    GlaxoSmithKline's Dividend Health Aug 09 2016 
    Can Novartis Win the Entresto Bet? Aug 03 2016 
    Tweedy Browne 2nd Quarter Shareholder Letter Aug 01 2016 
    Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
    Causeway International Value Fund May Performance Review Jul 08 2016 

    More From Other Websites
    Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data Aug 29 2016
    Almost The Whole World In This ETF's Hands Aug 29 2016
    Novartis convenes experts to discuss new technologies in healthcare at Novartis International... Aug 29 2016
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016
    Novartis AG (NVS) Announces Positive Phase III Results For MS Drug Aug 26 2016
    Novartis (NVS) Reports Positive Phase III Results on MS Drug Aug 26 2016
    Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary... Aug 25 2016
    Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares Aug 24 2016
    Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics Aug 24 2016
    Cyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe... Aug 23 2016
    Novartis: First-Class Pharmaceuticals Aug 19 2016
    5 Stocks That Beat The Market In A Crash Aug 18 2016
    Turkey's investigation into drugmaker Novartis 'ongoing' -official Aug 17 2016
    Turkey's investigation into drugmaker Novartis 'ongoing' -official Aug 17 2016
    Turkey's investigation into drugmaker Novartis 'ongoing' - official Aug 17 2016
    CSL to hike spending after profit fall Aug 17 2016
    CSL to raise $US500m after mixed results Aug 16 2016
    Novartis Needs to Stem the Bleeding From Gleevec Decline Aug 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)